Goldberg Andrew D. 4

4 · Tarsus Pharmaceuticals, Inc. · Filed Jun 16, 2026

AI-generated summary of this filing

Updated Jun 16, 2026

Tarsus (TARS) Director Andrew Goldberg Receives 2,954 Shares

What Happened

Andrew D. Goldberg, a non‑employee director of Tarsus Pharmaceuticals (TARS), had 2,954 shares issued on June 12, 2026 upon settlement of vested restricted stock units (RSUs). The Form 4 records an acquisition of 2,954 shares (derivative conversion) and a corresponding derivative disposition of 2,954 shares at $0.00. The filing was submitted on June 16, 2026.

Key Details

Transaction date: June 12, 2026; Form 4 filed: June 16, 2026 (timely).
Reported items: Exercise/conversion of derivative (code M) — 2,954 shares acquired; matching derivative disposition of 2,954 shares at $0.00.
Price/consideration: No purchase price reported (shares issued upon RSU settlement).
Shares owned after transaction: Not specified in the filing.
Footnotes: RSUs represent contingent rights to receive one share each; these RSUs were granted on June 12, 2025 in connection with service as a non‑employee director and vested in full on the one‑year anniversary (per the filing).

Context

This was an RSU settlement (award conversion to common stock), a routine form of director compensation rather than an open‑market purchase or sale. The filing records both the issuance (acquisition) and a $0.00 derivative disposition; the Form does not provide an economic explanation for the disposition. Such award settlements are not direct buy/sell signals but do increase insider ownership when shares remain outstanding.

Form 4

Period: 2026-06-12

Director

Transactions

Exercise/Conversion
Common Stock
[F1]
2026-06-12+2,954→ 19,654 total
Exercise/Conversion
Restricted Stock Units
[F2][F3]
2026-06-12−2,954→ 0 total
→ Common Stock (2,954 underlying)

Footnotes (3)

[F1]The shares were issued pursuant to settlement of vested Restricted Stock Units ("RSUs"). Each RSU represents a contingent right to receive one share of the Company's common stock.
[F2]Each RSU represents a contingent right to receive one share of the Company's common stock.
[F3]RSUs granted on June 12, 2025, in connection with the Reporting Person's service as a non-employee director as of the Company's 2025 annual meeting of stockholders. The RSUs will vest in full on the one-year anniversary of the date of grant, subject to the non-employee director's continuous service.

Signature

/s/ Jeffrey Farrow, Attorney-in-Fact|2026-06-16

1 file